Q2 2023 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2023-08-14 · accession 0000899140-23-000886
$1.00B
Reported value
11
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G01767105 | ALKS | ALKERMES PLC | $439.5M | 43.7% | 14,040,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $183.2M | 18.2% | 643,000 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $174.4M | 17.4% | 16,390,000 | Common | SOLE |
| 45781M101 | INVA | INNOVIVA INC | $92.6M | 9.22% | 7,277,000 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $70.9M | 7.06% | 920,400 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $21.8M | 2.17% | 231,300 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $8.7M | 0.86% | 2,632,900 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $5.8M | 0.58% | 4,910,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $5.5M | 0.54% | 775,000 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $1.9M | 0.19% | 618,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $272,219 | 0.03% | 185,183 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.